Shenzhen Mindray Bio-Medical Electronics Co Ltd

Shenzhen Mindray Bio-Medical Electronics Co Ltd maintains a conservative capital structure characterized by minimal leverage and strong liquidity. The company reports a debt-to-equity ratio of 0.01, indicating negligible reliance on long-term debt financing. Total liabilities stand at 21.17 billion CNY against total equity of 38.09 billion CNY, resulting in a current ratio of 2.36, which suggests ample short-term assets to cover immediate obligations. Cash and equivalents total 746.42 million CNY, while operating cash flow reaches 10.14 billion CNY, demonstrating robust cash generation capabilities. The risk assessment flags liquidity risk as low, consistent with these balance sheet metrics.

Profitability metrics indicate efficient capital utilization, with a return on equity (ROE) of 20.57% and a return on assets (ROA) of 13.22%. The company generates a gross profit of 19.75 billion CNY on revenue of 33.28 billion CNY, yielding a gross margin of approximately 59.4%. Operating income is 9.77 billion CNY, leading to a net income of 8.14 billion CNY, which reflects a net margin of roughly 24.4%. These returns are supported by a price-to-earnings ratio of 21.78 and an EV/EBITDA of 18.36, suggesting the market values the company’s consistent profitability.

Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of product mix or geographic exposure. However, the company’s total revenue of 33.28 billion CNY indicates a significant scale within the health care equipment sector. The absence of specific segment data limits the ability to assess diversification risks or regional dependencies, but the overall financial stability suggests a resilient business model.

Growth trajectory analysis is constrained by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to calculate year-over-year growth rates or assess the consistency of earnings expansion. The current financial snapshot provides a static view of performance, highlighting strong absolute profitability but lacking the temporal context required for trend analysis.

Risk factors are assessed as low for both liquidity and dilution, with no immediate filing-based flags detected. The company’s low debt levels and strong cash flow generation mitigate financial distress risks. Dilution risk is also low, as basic and diluted shares outstanding are identical at 1.21 billion shares, indicating no significant options or convertible securities impacting share count. The primary risks appear to be operational or market-related rather than financial, given the robust balance sheet.

Recent events and market sentiment are reflected in analyst estimates, with a mean price target of 239.44 CNY and a median target of 247.00 CNY, implying significant upside from the current market price of 140.75 CNY. The mean recommendation is 1.58, with 12 strong buy and 13 buy ratings, indicating strong institutional confidence. No specific filing, news, or transcript observations are provided, but the analyst consensus suggests positive expectations for future performance.

Analysts project 63.1% upside to a mean price target of 239.44, reflecting strong buy consensus among 26 analysts.

The company maintains a negligible debt-to-equity ratio of 0.01, indicating minimal leverage risk compared to peers.

Net income CAGR of 0.4% over four years indicates stagnant long-term earnings growth potential.

Free cash flow turned negative in fiscal 2024, recording a deficit of 769 million CNY.

Revenue ¥8.35B, +1,4% YoY; Operating income −17,2% YoY.

• ▍Revenue ¥8.35B, +1,4% YoY
• ▍Operating income −17,2% YoY
• ▍Net income −11,4% YoY
• ▍Net margin 27.9%

Revenue ¥7.45B, +2,9% YoY; Operating income −16,6% YoY.

• ▍Revenue ¥7.45B, +2,9% YoY
• ▍Operating income −16,6% YoY
• ▍Net income −45,1% YoY
• ▍Net margin 7.6%

Revenue ¥9.09B, +1,5% YoY; Operating income −13,9% YoY.

• ▍Revenue ¥9.09B, +1,5% YoY
• ▍Operating income −13,9% YoY
• ▍Net income −18,7% YoY
• ▍Net margin 27.5%

Revenue ¥8.51B, −23,8% YoY; Operating income −42,6% YoY.

• ▍Revenue ¥8.51B, −23,8% YoY
• ▍Operating income −42,6% YoY
• ▍Net income −44,5% YoY
• ▍Net margin 28.7%

Revenue ¥8.24B; Operating income ¥3.05B.

• ▍Revenue ¥8.24B
• ▍Operating income ¥3.05B
• ▍Net margin 31.9%

Revenue ¥7.24B; Operating income ¥1.02B.

• ▍Revenue ¥7.24B
• ▍Operating income ¥1.02B
• ▍Net margin 14.2%

Revenue ¥8.95B; Operating income ¥3.52B.

• ▍Revenue ¥8.95B
• ▍Operating income ¥3.52B
• ▍Net margin 34.4%

Revenue ¥11.16B; Operating income ¥5.01B.

• ▍Revenue ¥11.16B
• ▍Operating income ¥5.01B
• ▍Net margin 39.4%

Revenue ¥33.28B, −9,4% YoY; Operating income −25,4% YoY.

• ▍Revenue ¥33.28B, −9,4% YoY
• ▍Operating income −25,4% YoY
• ▍Net income −30,3% YoY
• ▍Free cash flow +4,8% YoY
• ▍Net margin 24.4%

Revenue ¥36.73B, +5,1% YoY; Operating income +0,3% YoY.

• ▍Revenue ¥36.73B, +5,1% YoY
• ▍Operating income +0,3% YoY
• ▍Net income +0,7% YoY
• ▍Free cash flow +412,7% YoY
• ▍Net margin 31.8%

Revenue ¥34.93B, +15,0% YoY; Operating income +18,8% YoY.

• ▍Revenue ¥34.93B, +15,0% YoY
• ▍Operating income +18,8% YoY
• ▍Net income +20,6% YoY
• ▍Free cash flow −117,7% YoY
• ▍Net margin 33.2%

Revenue ¥30.37B, +20,2% YoY; Operating income +21,3% YoY.

• ▍Revenue ¥30.37B, +20,2% YoY
• ▍Operating income +21,3% YoY
• ▍Net income +20,1% YoY
• ▍Free cash flow +2,0% YoY
• ▍Net margin 31.6%